Literature DB >> 19758094

Risk factors for respiratory failure associated with respiratory syncytial virus infection in adults.

Coley B Duncan1, Edward E Walsh, Derick R Peterson, F Eun-Hyung Lee, Ann R Falsey.   

Abstract

Risk factors associated with respiratory failure during respiratory syncytial virus (RSV) infection have not been assessed in adults. We identified RSV by quantitative reverse transcription polymerase chain reaction in 58 adults during the 2007-2008 winter. Clinical variables and respiratory secretion viral loads were compared in 26 outpatients and 32 inpatients. Cardiopulmonary diseases were more common among inpatients than outpatients (91% vs 31%, P = .0001), whereas mean RSV load was similar. Nasal viral load was higher in ventilated vs nonventilated hospitalized patients (log(10) 3.7 +/- 1.7 plaque-forming units (PFUs)/mL vs 2.4 +/- 1.1 PFUs/mL, P = .02), and high viral load was independently associated with respiratory failure.

Entities:  

Mesh:

Year:  2009        PMID: 19758094      PMCID: PMC2896971          DOI: 10.1086/605948

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

1.  An outbreak of respiratory syncytial virus in a bone marrow transplant center.

Authors:  R D Harrington; T M Hooton; R C Hackman; G A Storch; B Osborne; C A Gleaves; A Benson; J D Meyers
Journal:  J Infect Dis       Date:  1992-06       Impact factor: 5.226

2.  Relationship of serum antibody to risk of respiratory syncytial virus infection in elderly adults.

Authors:  A R Falsey; E E Walsh
Journal:  J Infect Dis       Date:  1998-02       Impact factor: 5.226

3.  A simple and reproducible method for collecting nasal secretions in frail elderly adults, for measurement of virus-specific IgA.

Authors:  E E Walsh; A R Falsey
Journal:  J Infect Dis       Date:  1999-05       Impact factor: 5.226

4.  Detection of respiratory syncytial virus in adults with chronic obstructive pulmonary disease.

Authors:  Ann R Falsey; Maria A Formica; Patricia A Hennessey; Mary M Criddle; Wayne M Sullender; Edward E Walsh
Journal:  Am J Respir Crit Care Med       Date:  2005-12-30       Impact factor: 21.405

5.  Respiratory syncytial virus infection in elderly and high-risk adults.

Authors:  Ann R Falsey; Patricia A Hennessey; Maria A Formica; Christopher Cox; Edward E Walsh
Journal:  N Engl J Med       Date:  2005-04-28       Impact factor: 91.245

6.  Respiratory syncytial virus load predicts disease severity in previously healthy infants.

Authors:  John P DeVincenzo; Chadi M El Saleeby; Andrew J Bush
Journal:  J Infect Dis       Date:  2005-04-21       Impact factor: 5.226

7.  Respiratory syncytial virus infection among intubated adults in a university medical intensive care unit.

Authors:  G G Guidry; C A Black-Payne; D K Payne; R M Jamison; R B George; J A Bocchini
Journal:  Chest       Date:  1991-11       Impact factor: 9.410

8.  Risk factors for severe respiratory syncytial virus infection in elderly persons.

Authors:  Edward E Walsh; Derick R Peterson; Ann R Falsey
Journal:  J Infect Dis       Date:  2004-01-09       Impact factor: 5.226

Review 9.  Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection.

Authors:  Robert C Welliver
Journal:  J Pediatr       Date:  2003-11       Impact factor: 4.406

10.  Viral respiratory infections in the institutionalized elderly: clinical and epidemiologic findings.

Authors:  A R Falsey; J J Treanor; R F Betts; E E Walsh
Journal:  J Am Geriatr Soc       Date:  1992-02       Impact factor: 5.562

View more
  33 in total

1.  Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB/c mice.

Authors:  Gertrud U Radu; Hayat Caidi; Congrong Miao; Ralph A Tripp; Larry J Anderson; Lia M Haynes
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

2.  Circulating antibody-secreting cells during acute respiratory syncytial virus infection in adults.

Authors:  F Eun-Hyung Lee; Ann R Falsey; Jessica L Halliley; Iñaki Sanz; Edward E Walsh
Journal:  J Infect Dis       Date:  2010-10-27       Impact factor: 5.226

Review 3.  Respiratory Syncytial Virus Infection: An Illness for All Ages.

Authors:  Edward E Walsh
Journal:  Clin Chest Med       Date:  2016-12-27       Impact factor: 2.878

Review 4.  Respiratory viral infections in hematopoietic stem cell and solid organ transplant recipients.

Authors:  S Samuel Weigt; Aric L Gregson; Jane C Deng; Joseph P Lynch; John A Belperio
Journal:  Semin Respir Crit Care Med       Date:  2011-08-19       Impact factor: 3.119

5.  Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection.

Authors:  Amy S Espeseth; Pedro J Cejas; Michael P Citron; Dai Wang; Daniel J DiStefano; Cheryl Callahan; Gregory O' Donnell; Jennifer D Galli; Ryan Swoyer; Sinoeun Touch; Zhiyun Wen; Joseph Antonello; Lan Zhang; Jessica A Flynn; Kara S Cox; Daniel C Freed; Kalpit A Vora; Kapil Bahl; Andrew H Latham; Jeffrey S Smith; Marian E Gindy; Giuseppe Ciaramella; Daria Hazuda; Christine A Shaw; Andrew J Bett
Journal:  NPJ Vaccines       Date:  2020-02-14       Impact factor: 7.344

Review 6.  Respiratory syncytial virus vaccine development.

Authors:  Julia L Hurwitz
Journal:  Expert Rev Vaccines       Date:  2011-10       Impact factor: 5.217

7.  Respiratory syncytial virus infection in older adults: an under-recognized problem.

Authors:  Angela R Branche; Ann R Falsey
Journal:  Drugs Aging       Date:  2015-04       Impact factor: 3.923

8.  Viral shedding and immune responses to respiratory syncytial virus infection in older adults.

Authors:  Edward E Walsh; Derick R Peterson; Aja E Kalkanoglu; Frances Eun-Hyung Lee; Ann R Falsey
Journal:  J Infect Dis       Date:  2013-02-04       Impact factor: 5.226

9.  A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults.

Authors:  Antonios O Aliprantis; Christine A Shaw; Paul Griffin; Nicholas Farinola; Radha A Railkar; Xin Cao; Wen Liu; Jeffrey R Sachs; Christine J Swenson; Heather Lee; Kara S Cox; Daniel S Spellman; Colleen J Winstead; Igor Smolenov; Eseng Lai; Tal Zaks; Amy S Espeseth; Lori Panther
Journal:  Hum Vaccin Immunother       Date:  2020-10-29       Impact factor: 3.452

Review 10.  The diagnosis of viral respiratory disease in older adults.

Authors:  H Keipp Talbot; Ann R Falsey
Journal:  Clin Infect Dis       Date:  2010-03-01       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.